This exciting collaboration combines Tempus AI, Inc.’s (NASDAQ: TEM) innovative technology platform, huge volumes of real world data, and BioCorteX’s groundbreaking foundational emulator – Carbon MirrorTM. Working together, BioCorteX and Tempus will seek to uncover the previously hidden role of bacteria within the TME. It is increasingly recognised that bacteria play a pivotal role in the TME and have the potential to disrupt the design, development, and delivery of therapeutic treatments including small molecules and ADCs. Being able to understand these complex relationships through time requires innovative solutions.
There is a deep synergy between the technical capabilities of both companies with Tempus knowledge and data supercharging the Carbon Mirror platform to perform millions of in-silico trials, increasing the clinical success of drug development for pharma partnerships. Seeking to accelerate the development of novel insights throughout the therapeutic lifecycle, BioCorteX is forging a path to delivering truly personalised treatment regimes to patients. This, combined with Tempus’s far-reaching and unique approach to patient-centric care, will increase clinical success throughout the pharmaceutical pipeline.
This collaboration will initially focus on triple-negative breast cancer. Moving forward, these capabilities will be extended and applied across a wider range of cancer and disease areas.
“We are looking forward to working with BioCorteX to better understand intratumoral bacterial populations and the potential impact on therapeutic response,” said Kate Sasser, Chief Scientific Officer at Tempus. “Our database is uniquely positioned to support this research that aims to better understand tumour makeup on a much deeper level.”
“BioCorteX and Tempus have a shared commitment to patients and their families. This alignment enables us to integrate our technological approaches, accelerating and delivering new solutions in cancer diagnostics and care.” Dr Nik Sharma MB, PhD, CEO & co-founder BioCorteX.
